Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Mich. , Aug. 27, 2015  Neogen Corporation ... acquired the stock of United Kingdom ... of microbiological culture media and diagnostic systems. ... grown into a leading provider of microbial testing and ... clinical testing markets. The company currently sells into more ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... in Personalized Medicine, recently presented new data on the relationship of genetics and ... 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... venture capital in more deals in 2006, but the improvement ... Ernst & Young, LLP and Dow Jones ... in 2006, including a $12 .5 million round by ... for a total of $58.47 million. The total, up from ...
... Lance Armstrong is a unique phenomenon. He's a talented athlete, ... league by himself. Or is he? , ,As many people know, ... National Center for Health Statistics report released by the ... the second year in a row. , ,Cancer patients as political ...
... director of technology programs for the University of Wisconsin-Madison, is ... he demonstrates in Part II of this interview. In ... In Part II (below), he addresses creating a culture of ... also is a featured speaker at the Fusion 2007 ...
Cached Biology Technology:Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3Lance Armstrong and the future of cancer care 2Lance Armstrong and the future of cancer care 3Lance Armstrong and the future of cancer care 4Lance Armstrong and the future of cancer care 5
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... Mich. Solar power might be nature,s most plentiful and ... lure water insects away from critical breeding areas, a Michigan ... or other methods to break up the polarized reflection of ... likely to deposit eggs on the panels thinking that they ...
... a crime novel on a dime-store shelf. But "An Invitation to ... is very, very small. Rice University evolutionary biologists reported ... starve in a slime mold seem to have an advantage that ... that keep on eating into sacrificing themselves for the common good. ...
... AUGUSTA, Ga. The dietary supplement CDP-choline, sold as ... traumatic brain injury, may block skull and brain damage ... Medical College of Georgia researchers report. Alcohol ... lipid called ceramide, significantly increasing suicide among cells critical ...
Cached Biology News:Solar panels can attract breeding water insects 2A Dicty mystery solved 2Supplement may prevent alcohol-related brain, skull defects 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5 mm in diameter) in ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5mm in diameter) in comparison ...
... DNA Engine Opticon real-time PCR detection system ... fluorescence excitation (450-495 nm) and a photomultiplier ... Opticon system is built on an DNA ... thermal gradient feature. This item includes the ...
Biology Products: